Janney Montgomery Scott LLC Increases Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Janney Montgomery Scott LLC increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 8.3% during the 3rd quarter, Holdings Channel reports. The firm owned 51,155 shares of the company’s stock after purchasing an additional 3,912 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Cellebrite DI were worth $861,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pembroke Management LTD lifted its position in shares of Cellebrite DI by 104.9% during the 2nd quarter. Pembroke Management LTD now owns 1,535,726 shares of the company’s stock worth $18,352,000 after buying an additional 786,310 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Cellebrite DI by 26.8% during the first quarter. Acadian Asset Management LLC now owns 2,896,497 shares of the company’s stock valued at $32,062,000 after acquiring an additional 612,787 shares during the last quarter. Meitav Investment House Ltd. lifted its holdings in Cellebrite DI by 29.7% during the third quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company’s stock worth $34,797,000 after acquiring an additional 473,293 shares during the period. Ashford Capital Management Inc. boosted its position in Cellebrite DI by 23.5% in the first quarter. Ashford Capital Management Inc. now owns 1,841,240 shares of the company’s stock worth $20,401,000 after purchasing an additional 350,140 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in Cellebrite DI by 22.1% in the 2nd quarter. Renaissance Technologies LLC now owns 1,183,700 shares of the company’s stock valued at $14,145,000 after purchasing an additional 214,600 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their target price on Cellebrite DI from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Needham & Company LLC lifted their price objective on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Lake Street Capital lifted their price target on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Craig Hallum increased their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $20.29.

Cellebrite DI Stock Down 1.4 %

CLBT opened at $17.70 on Friday. The company has a market capitalization of $3.64 billion, a price-to-earnings ratio of -11.42, a PEG ratio of 2.50 and a beta of 1.50. The firm has a 50-day moving average price of $17.74 and a 200-day moving average price of $14.54. Cellebrite DI Ltd. has a twelve month low of $7.64 and a twelve month high of $21.00.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. During the same period in the previous year, the business earned $0.09 EPS. Cellebrite DI’s revenue was up 27.0% compared to the same quarter last year. On average, sell-side analysts expect that Cellebrite DI Ltd. will post 0.31 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.